1
|
Braden K, Castro DC. Correction: Kappa opioid receptors as modulators of novelty processing. Neuropsychopharmacology 2023:10.1038/s41386-023-01584-6. [PMID: 37138101 DOI: 10.1038/s41386-023-01584-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 05/05/2023]
Affiliation(s)
- Kathryn Braden
- Mallinckrodt Institute of Radiology, Washington University School of Medicine, Saint Louis, MO, 63110, USA
| | - Daniel C Castro
- Mallinckrodt Institute of Radiology, Washington University School of Medicine, Saint Louis, MO, 63110, USA.
| |
Collapse
|
2
|
Braden K, Castro DC. Kappa opioid receptors as modulators of novelty processing. Neuropsychopharmacology 2023; 48:848-849. [PMID: 36922627 PMCID: PMC10156680 DOI: 10.1038/s41386-023-01561-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/27/2023] [Accepted: 03/01/2023] [Indexed: 03/18/2023]
Affiliation(s)
- Kathryn Braden
- Mallinckrodt Institute of Radiology, Washington University School of Medicine, Saint Louis, MO, 63110, USA
| | - Daniel C Castro
- Mallinckrodt Institute of Radiology, Washington University School of Medicine, Saint Louis, MO, 63110, USA.
| |
Collapse
|
3
|
Braden K, Campolo M, Li Y, Chen Z, Doyle TM, Giancotti LA, Esposito E, Zhang J, Cuzzocrea S, Arnatt CK, Salvemini D. Activation of GPR183 by 7 α,25-Dihydroxycholesterol Induces Behavioral Hypersensitivity through Mitogen-Activated Protein Kinase and Nuclear Factor- κB. J Pharmacol Exp Ther 2022; 383:172-181. [PMID: 36116795 PMCID: PMC9553113 DOI: 10.1124/jpet.122.001283] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2022] [Accepted: 08/17/2022] [Indexed: 01/07/2023] Open
Abstract
Emerging evidence implicates the G-protein coupled receptor (GPCR) GPR183 in the development of neuropathic pain. Further investigation of the signaling pathways downstream of GPR183 is needed to support the development of GPR183 antagonists as analgesics. In rodents, intrathecal injection of its ligand, 7α,25-dihydroxycholesterol (7α,25-OHC), causes time-dependent development of mechano-and cold- allodynia (behavioral hypersensitivity). These effects are blocked by the selective small molecule GPR183 antagonist, SAE-14. However, the molecular mechanisms engaged downstream of GPR183 in the spinal cord are not known. Here, we show that 7α,25-OHC-induced behavioral hypersensitivity is Gα i dependent, but not β-arrestin 2-dependent. Non-biased transcriptomic analyses of dorsal-horn spinal cord (DH-SC) tissues harvested at the time of peak hypersensitivity implicate potential contributions of mitogen-activated protein kinase (MAPK) and nuclear factor κB (NF-κB). In support, we found that the development of 7α,25-OHC/GPR183-induced mechano-allodynia was associated with significant activation of MAPKs (extracellular signal-regulated kinase [ERK], p38) and redox-sensitive transcription factors (NF-κB) and increased formation of inflammatory and neuroexcitatory cytokines. SAE-14 blocked these effects and behavioral hypersensitivity. Our findings provide novel mechanistic insight into how GPR183 signaling in the spinal cord produces hypersensitivity through MAPK and NF-κB activation. SIGNIFICANCE STATEMENT: Using a multi-disciplinary approach, we have characterized the molecular mechanisms underpinning 7α,25-OHC/GPR183-induced hypersensitivity in mice. Intrathecal injections of the GPR183 agonist 7α,25-OHC induce behavioral hypersensitivity, and these effects are blocked by the selective GPR183 antagonist SAE-14. We found that 7α,25-OHC-induced allodynia is dependent on MAPK and NF-κB signaling pathways and results in an increase in pro-inflammatory cytokine expression. This study provides a first insight into how GPR183 signaling in the spinal cord is pronociceptive.
Collapse
Affiliation(s)
- Kathryn Braden
- Department of Pharmacology and Physiology, Saint Louis University School of Medicine, Saint Louis, Missouri (K.B., Y.L., Z.C., T.M.D., L.A.G., J.Z., C.K.A., D.S.); Henry and Amelia Nasrallah Center for Neuroscience, Saint Louis University, Saint Louis, Missouri (K.B., Y.L., Z.C., T.M.D., L.A.G., J.Z., C.K.A.,D.S.); Department of Clinical and Experimental Medicine and Pharmacology, University of Messina, Messina, Italy (M.C., E.E., S.C.); and Department of Chemistry, Saint Louis University, Saint Louis, Missouri (C.K.A.)
| | - Michela Campolo
- Department of Pharmacology and Physiology, Saint Louis University School of Medicine, Saint Louis, Missouri (K.B., Y.L., Z.C., T.M.D., L.A.G., J.Z., C.K.A., D.S.); Henry and Amelia Nasrallah Center for Neuroscience, Saint Louis University, Saint Louis, Missouri (K.B., Y.L., Z.C., T.M.D., L.A.G., J.Z., C.K.A.,D.S.); Department of Clinical and Experimental Medicine and Pharmacology, University of Messina, Messina, Italy (M.C., E.E., S.C.); and Department of Chemistry, Saint Louis University, Saint Louis, Missouri (C.K.A.)
| | - Ying Li
- Department of Pharmacology and Physiology, Saint Louis University School of Medicine, Saint Louis, Missouri (K.B., Y.L., Z.C., T.M.D., L.A.G., J.Z., C.K.A., D.S.); Henry and Amelia Nasrallah Center for Neuroscience, Saint Louis University, Saint Louis, Missouri (K.B., Y.L., Z.C., T.M.D., L.A.G., J.Z., C.K.A.,D.S.); Department of Clinical and Experimental Medicine and Pharmacology, University of Messina, Messina, Italy (M.C., E.E., S.C.); and Department of Chemistry, Saint Louis University, Saint Louis, Missouri (C.K.A.)
| | - Zhoumou Chen
- Department of Pharmacology and Physiology, Saint Louis University School of Medicine, Saint Louis, Missouri (K.B., Y.L., Z.C., T.M.D., L.A.G., J.Z., C.K.A., D.S.); Henry and Amelia Nasrallah Center for Neuroscience, Saint Louis University, Saint Louis, Missouri (K.B., Y.L., Z.C., T.M.D., L.A.G., J.Z., C.K.A.,D.S.); Department of Clinical and Experimental Medicine and Pharmacology, University of Messina, Messina, Italy (M.C., E.E., S.C.); and Department of Chemistry, Saint Louis University, Saint Louis, Missouri (C.K.A.)
| | - Timothy M Doyle
- Department of Pharmacology and Physiology, Saint Louis University School of Medicine, Saint Louis, Missouri (K.B., Y.L., Z.C., T.M.D., L.A.G., J.Z., C.K.A., D.S.); Henry and Amelia Nasrallah Center for Neuroscience, Saint Louis University, Saint Louis, Missouri (K.B., Y.L., Z.C., T.M.D., L.A.G., J.Z., C.K.A.,D.S.); Department of Clinical and Experimental Medicine and Pharmacology, University of Messina, Messina, Italy (M.C., E.E., S.C.); and Department of Chemistry, Saint Louis University, Saint Louis, Missouri (C.K.A.)
| | - Luigino Antonio Giancotti
- Department of Pharmacology and Physiology, Saint Louis University School of Medicine, Saint Louis, Missouri (K.B., Y.L., Z.C., T.M.D., L.A.G., J.Z., C.K.A., D.S.); Henry and Amelia Nasrallah Center for Neuroscience, Saint Louis University, Saint Louis, Missouri (K.B., Y.L., Z.C., T.M.D., L.A.G., J.Z., C.K.A.,D.S.); Department of Clinical and Experimental Medicine and Pharmacology, University of Messina, Messina, Italy (M.C., E.E., S.C.); and Department of Chemistry, Saint Louis University, Saint Louis, Missouri (C.K.A.)
| | - Emanuela Esposito
- Department of Pharmacology and Physiology, Saint Louis University School of Medicine, Saint Louis, Missouri (K.B., Y.L., Z.C., T.M.D., L.A.G., J.Z., C.K.A., D.S.); Henry and Amelia Nasrallah Center for Neuroscience, Saint Louis University, Saint Louis, Missouri (K.B., Y.L., Z.C., T.M.D., L.A.G., J.Z., C.K.A.,D.S.); Department of Clinical and Experimental Medicine and Pharmacology, University of Messina, Messina, Italy (M.C., E.E., S.C.); and Department of Chemistry, Saint Louis University, Saint Louis, Missouri (C.K.A.)
| | - Jinsong Zhang
- Department of Pharmacology and Physiology, Saint Louis University School of Medicine, Saint Louis, Missouri (K.B., Y.L., Z.C., T.M.D., L.A.G., J.Z., C.K.A., D.S.); Henry and Amelia Nasrallah Center for Neuroscience, Saint Louis University, Saint Louis, Missouri (K.B., Y.L., Z.C., T.M.D., L.A.G., J.Z., C.K.A.,D.S.); Department of Clinical and Experimental Medicine and Pharmacology, University of Messina, Messina, Italy (M.C., E.E., S.C.); and Department of Chemistry, Saint Louis University, Saint Louis, Missouri (C.K.A.)
| | - Salvatore Cuzzocrea
- Department of Pharmacology and Physiology, Saint Louis University School of Medicine, Saint Louis, Missouri (K.B., Y.L., Z.C., T.M.D., L.A.G., J.Z., C.K.A., D.S.); Henry and Amelia Nasrallah Center for Neuroscience, Saint Louis University, Saint Louis, Missouri (K.B., Y.L., Z.C., T.M.D., L.A.G., J.Z., C.K.A.,D.S.); Department of Clinical and Experimental Medicine and Pharmacology, University of Messina, Messina, Italy (M.C., E.E., S.C.); and Department of Chemistry, Saint Louis University, Saint Louis, Missouri (C.K.A.)
| | - Christopher Kent Arnatt
- Department of Pharmacology and Physiology, Saint Louis University School of Medicine, Saint Louis, Missouri (K.B., Y.L., Z.C., T.M.D., L.A.G., J.Z., C.K.A., D.S.); Henry and Amelia Nasrallah Center for Neuroscience, Saint Louis University, Saint Louis, Missouri (K.B., Y.L., Z.C., T.M.D., L.A.G., J.Z., C.K.A.,D.S.); Department of Clinical and Experimental Medicine and Pharmacology, University of Messina, Messina, Italy (M.C., E.E., S.C.); and Department of Chemistry, Saint Louis University, Saint Louis, Missouri (C.K.A.)
| | - Daniela Salvemini
- Department of Pharmacology and Physiology, Saint Louis University School of Medicine, Saint Louis, Missouri (K.B., Y.L., Z.C., T.M.D., L.A.G., J.Z., C.K.A., D.S.); Henry and Amelia Nasrallah Center for Neuroscience, Saint Louis University, Saint Louis, Missouri (K.B., Y.L., Z.C., T.M.D., L.A.G., J.Z., C.K.A.,D.S.); Department of Clinical and Experimental Medicine and Pharmacology, University of Messina, Messina, Italy (M.C., E.E., S.C.); and Department of Chemistry, Saint Louis University, Saint Louis, Missouri (C.K.A.)
| |
Collapse
|
4
|
Olayide II, Braden K, Latzo N, Salvemini D, Arnatt C. Structure Activity Relationship and Biological Evaluation of Small Molecule Antagonists for G‐Protein Coupled Receptor Associated with Neuropathic Pain. FASEB J 2022. [DOI: 10.1096/fasebj.2022.36.s1.r3159] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
5
|
Braden K, Campolo M, Chen Z, Giancotti L, Doyle TM, Esposito E, Zhang J, Cuzzocrea S, Arnatt CK, Salvemini D. Investigating the Molecular Mechanisms Driving 7α,25‐dihydroxycholesterol‐GPR183‐Induced Hypersensitivity. FASEB J 2022. [DOI: 10.1096/fasebj.2022.36.s1.r2071] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Kathryn Braden
- Pharmacology and PhysiologySaint Louis UniversitySt. LouisMO
- Henry and Amelia Nasrallah Center for NeuroscienceSaint Louis UniversitySt. LouisMO
| | - Michela Campolo
- Department of Clinical and Experimental Medicine and PharmacologyUniversity of MessinaMessina
| | - Zhoumou Chen
- Pharmacology and PhysiologySaint Louis UniversitySt. LouisMO
- Henry and Amelia Nasrallah Center for NeuroscienceSaint Louis UniversitySt. LouisMO
| | - Luigi Giancotti
- Pharmacology and PhysiologySaint Louis UniversitySt. LouisMO
- Henry and Amelia Nasrallah Center for NeuroscienceSaint Louis UniversitySt. LouisMO
| | - Timothy M. Doyle
- Pharmacology and PhysiologySaint Louis UniversitySt. LouisMO
- Henry and Amelia Nasrallah Center for NeuroscienceSaint Louis UniversitySt. LouisMO
| | - Emanuela Esposito
- Department of Clinical and Experimental Medicine and PharmacologyUniversity of MessinaMessina
| | - Jinsong Zhang
- Pharmacology and PhysiologySaint Louis UniversitySt. LouisMO
- Henry and Amelia Nasrallah Center for NeuroscienceSaint Louis UniversitySt. LouisMO
| | - Salvatore Cuzzocrea
- Department of Clinical and Experimental Medicine and PharmacologyUniversity of MessinaMessina
| | - Christopher K. Arnatt
- Pharmacology and PhysiologySaint Louis UniversitySt. LouisMO
- Henry and Amelia Nasrallah Center for NeuroscienceSaint Louis UniversitySt. LouisMO
- ChemistrySaint Louis UniversitySt. LouisMO
| | - Daniela Salvemini
- Pharmacology and PhysiologySaint Louis UniversitySt. LouisMO
- Henry and Amelia Nasrallah Center for NeuroscienceSaint Louis UniversitySt. LouisMO
| |
Collapse
|
6
|
Braden K, Stratton HJ, Salvemini D, Khanna R. Small molecule targeting NaV1.7 via inhibition of the CRMP2-Ubc9 interaction reduces and prevents pain chronification in a mouse model of oxaliplatin-induced neuropathic pain. Neurobiol Pain 2022; 11:100082. [PMID: 35024498 PMCID: PMC8733339 DOI: 10.1016/j.ynpai.2021.100082] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/07/2021] [Revised: 12/21/2021] [Accepted: 12/21/2021] [Indexed: 12/24/2022]
Abstract
Treatment with anti-neoplastic agents can lead to the development of chemotherapy induced peripheral neuropathy (CIPN), which is long lasting and often refractory to treatment. This neuropathic pain develops along dermatomes innervated by peripheral nerves with cell bodies located in the dorsal root ganglia (DRG). The voltage-gated sodium channel NaV1.7 is expressed at high levels in peripheral nerve tissues and has been implicated in the development of CIPN. Efforts to develop novel analgesics directly inhibiting NaV1.7 have been unsuccessful, and our group has pioneered an alternative approach based on indirect modulation of channel trafficking by the accessory protein collapsin response mediator protein 2 (CRMP2). We have recently reported a small molecule, compound 194, that inhibits CRMP2 SUMOylation by the E2 SUMO-conjugating enzyme Ubc9 (Cai et al. , Sci. Transl. Med. 2021 13(6 1 9):eabh1314). Compound 194 is a potent and selective inhibitor of NaV1.7 currents in DRG neurons and reverses mechanical allodynia in models of surgical, inflammatory, and neuropathic pain, including spared nerve injury and paclitaxelinduced peripheral neuropathy. Here we report that, in addition to its reported effects in rats, 194 also reduces mechanical allodynia in male CD-1 mice treated with platinumcomplex agent oxaliplatin. Importantly, treatment with 194 prevented the development of mechanical allodynia when co-administered with oxaliplatin. No effects were observed on the body weight of animals treated with oxaliplatin or 194 throughout the study period. These findings support the notion that 194 is a robust inhibitor of CIPN that reduces established neuropathic pain and prevents the emergence of neuropathic pain during treatment with multiple anti-neoplastic agents in both mice and rats.
Collapse
Key Words
- CIPN, chemotherapy induced peripheral neuropathy
- CRISPR, clustered regularly interspaced short palindromic repeats
- CRMP2
- CRMP2, collapsin response mediator protein 2
- Chemotherapy
- DRG, dorsal root ganglia
- NaV1.7
- NaV1.7, voltage-gated sodium channel family 1 isoform 7
- Neuropathy
- Oxaliplatin
- PWT, paw withdrawal threshold
- SNI, spared nerve injury
- SUMO, smallubiquitin like modifier
- SUMOylation
- TTX, tetrodotoxin
- TTX-R, tetrodotoxin-resistant
- TTX-S, tetrodotoxin-sensitive
- Ubc9, E2 SUMO-conjugating enzyme
- t-CSM, tat-CRMP2 SUMOylation motif
Collapse
Affiliation(s)
- Kathryn Braden
- Department of Pharmacology and Physiology, Saint Louis University School of Medicine, St. Louis, MO 63104, USA
- Henry and Amelia Nasrallah Center for Neuroscience, Saint Louis University School of Medicine, St. Louis, MO 63104, USA
| | - Harrison J. Stratton
- Department of Pharmacology, College of Medicine, the University of Arizona, Tucson, AZ 85724, USA
| | - Daniela Salvemini
- Department of Pharmacology and Physiology, Saint Louis University School of Medicine, St. Louis, MO 63104, USA
- Henry and Amelia Nasrallah Center for Neuroscience, Saint Louis University School of Medicine, St. Louis, MO 63104, USA
| | - Rajesh Khanna
- Department of Pharmacology, College of Medicine, the University of Arizona, Tucson, AZ 85724, USA
- Comprehensive Pain and Addiction Center, The University of Arizona, Tucson, AZ 85724, USA
| |
Collapse
|
7
|
Doyle TM, Braden K, Harada CM, Mufti F, Schafer RM, Salvemini D. Novel Non-Opioid Based Therapeutics for Chronic Neuropathic Pain. Mo Med 2021; 118:327-333. [PMID: 34373667 PMCID: PMC8343628] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 06/13/2023]
Abstract
Chronic neuropathic pain is currently a major health issue in U.S. complicated by the lack of non-opioid analgesic alternatives. Our investigations led to the discovery of major signaling pathways involved in the transition of acute to chronic neuropathic pain and the identification of several targets for therapeutic intervention. Our translational approach has facilitated the advancement of novel medicines for chronic neuropathic pain that are in advanced clinical development and clinical trials.
Collapse
Affiliation(s)
- Timothy M Doyle
- Department of Pharmacology and Physiology and the Henry and Amelia Nasrallah Center for Neuroscience, Saint Louis University School of Medicine, St. Louis, Missouri
| | - Kathryn Braden
- Department of Pharmacology and Physiology and the Henry and Amelia Nasrallah Center for Neuroscience, Saint Louis University School of Medicine, St. Louis, Missouri
| | - Caron M Harada
- Department of Pharmacology and Physiology and the Henry and Amelia Nasrallah Center for Neuroscience, Saint Louis University School of Medicine, St. Louis, Missouri
| | - Fatma Mufti
- Department of Pharmacology and Physiology and the Henry and Amelia Nasrallah Center for Neuroscience, Saint Louis University School of Medicine, St. Louis, Missouri
| | - Rachel M Schafer
- Department of Pharmacology and Physiology and the Henry and Amelia Nasrallah Center for Neuroscience, Saint Louis University School of Medicine, St. Louis, Missouri
| | - Daniela Salvemini
- Department of Pharmacology and Physiology and the Henry and Amelia Nasrallah Center for Neuroscience, Saint Louis University School of Medicine, St. Louis, Missouri
| |
Collapse
|
8
|
Doyle TM, Hutchinson MR, Braden K, Janes K, Staikopoulos V, Chen Z, Neumann WL, Spiegel S, Salvemini D. Sphingosine-1-phosphate receptor subtype 1 activation in the central nervous system contributes to morphine withdrawal in rodents. J Neuroinflammation 2020; 17:314. [PMID: 33092620 PMCID: PMC7584082 DOI: 10.1186/s12974-020-01975-2] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2020] [Accepted: 09/30/2020] [Indexed: 01/08/2023] Open
Abstract
Opioid therapies for chronic pain are undermined by many adverse side effects that reduce their efficacy and lead to dependence, abuse, reduced quality of life, and even death. We have recently reported that sphingosine-1-phosphate (S1P) 1 receptor (S1PR1) antagonists block the development of morphine-induced hyperalgesia and analgesic tolerance. However, the impact of S1PR1 antagonists on other undesirable side effects of opioids, such as opioid-induced dependence, remains unknown. Here, we demonstrate that naloxone-precipitated morphine withdrawal in mice altered de novo sphingolipid metabolism in the dorsal horn of the spinal cord and increased S1P that accompanied the manifestation of several withdrawal behaviors. Blocking de novo sphingolipid metabolism with intrathecal administration of myriocin, an inhibitor of serine palmitoyltransferase, blocked naloxone-precipitated withdrawal. Noteworthy, we found that competitive (NIBR-15) and functional (FTY720) S1PR1 antagonists attenuated withdrawal behaviors in mice. Mechanistically, at the level of the spinal cord, naloxone-precipitated withdrawal was associated with increased glial activity and formation of the potent inflammatory/neuroexcitatory cytokine interleukin-1β (IL-1β); these events were attenuated by S1PR1 antagonists. These results provide the first molecular insight for the role of the S1P/S1PR1 axis during opioid withdrawal. Our data identify S1PR1 antagonists as potential therapeutics to mitigate opioid-induced dependence and support repurposing the S1PR1 functional antagonist FTY720, which is FDA-approved for multiple sclerosis, as an opioid adjunct.
Collapse
Affiliation(s)
- Timothy M Doyle
- Henry and Amelia Nasrallah Center for Neuroscience, Saint Louis University School of Medicine, 1402 South Grand Blvd, St. Louis, MO, 63104, USA.,Department of Pharmacology and Physiology, Saint Louis University School of Medicine, 1402 South Grand Blvd, St. Louis, MO, 63104, USA
| | - Mark R Hutchinson
- Discipline of Physiology, University of Adelaide, Adelaide, South Australia, 5005, Australia.,Institute for Photonics and Advanced Sensing, University of Adelaide, Adelaide, South Australia, 5005, Australia.,ARC Centre of Excellence for Nanoscale BioPhotonics, University of Adelaide, Adelaide, South Australia, 5005, Australia
| | - Kathryn Braden
- Henry and Amelia Nasrallah Center for Neuroscience, Saint Louis University School of Medicine, 1402 South Grand Blvd, St. Louis, MO, 63104, USA.,Department of Pharmacology and Physiology, Saint Louis University School of Medicine, 1402 South Grand Blvd, St. Louis, MO, 63104, USA
| | - Kali Janes
- Department of Pharmacology and Physiology, Saint Louis University School of Medicine, 1402 South Grand Blvd, St. Louis, MO, 63104, USA
| | - Vicky Staikopoulos
- Discipline of Physiology, University of Adelaide, Adelaide, South Australia, 5005, Australia.,Institute for Photonics and Advanced Sensing, University of Adelaide, Adelaide, South Australia, 5005, Australia.,ARC Centre of Excellence for Nanoscale BioPhotonics, University of Adelaide, Adelaide, South Australia, 5005, Australia
| | - Zhoumou Chen
- Henry and Amelia Nasrallah Center for Neuroscience, Saint Louis University School of Medicine, 1402 South Grand Blvd, St. Louis, MO, 63104, USA.,Department of Pharmacology and Physiology, Saint Louis University School of Medicine, 1402 South Grand Blvd, St. Louis, MO, 63104, USA
| | - William L Neumann
- Department of Pharmaceutical Sciences, School of Pharmacy, Southern Illinois University Edwardsville, 200 University Park, Edwardsville, IL, 62026, USA
| | - Sarah Spiegel
- Department of Biochemistry and Molecular Biology, Virginia Commonwealth University, School of Medicine, 1101 E Marshall St, Richmond, VA, 23298, USA
| | - Daniela Salvemini
- Henry and Amelia Nasrallah Center for Neuroscience, Saint Louis University School of Medicine, 1402 South Grand Blvd, St. Louis, MO, 63104, USA. .,Department of Pharmacology and Physiology, Saint Louis University School of Medicine, 1402 South Grand Blvd, St. Louis, MO, 63104, USA.
| |
Collapse
|
9
|
Braden K, Giancotti LA, Chen Z, DeLeon C, Latzo N, Boehn T, D'Cunha N, Thompson BM, Doyle TM, McDonald JG, Walker JK, Kolar GR, Arnatt CK, Salvemini D. GPR183-Oxysterol Axis in Spinal Cord Contributes to Neuropathic Pain. J Pharmacol Exp Ther 2020; 375:367-375. [PMID: 32913007 DOI: 10.1124/jpet.120.000105] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2020] [Accepted: 08/25/2020] [Indexed: 12/31/2022] Open
Abstract
Neuropathic pain is a debilitating public health concern for which novel non-narcotic therapeutic targets are desperately needed. Using unbiased transcriptomic screening of the dorsal horn spinal cord after nerve injury we have identified that Gpr183 (Epstein-Barr virus-induced gene 2) is upregulated after chronic constriction injury (CCI) in rats. GPR183 is a chemotactic receptor known for its role in the maturation of B cells, and the endogenous ligand is the oxysterol 7α,25-dihydroxycholesterol (7α,25-OHC). The role of GPR183 in the central nervous system is not well characterized, and its role in pain is unknown. The profile of commercially available probes for GPR183 limits their use as pharmacological tools to dissect the roles of this receptor in pathophysiological settings. Using in silico modeling, we have screened a library of 5 million compounds to identify several novel small-molecule antagonists of GPR183 with nanomolar potency. These compounds are able to antagonize 7α,25-OHC-induced calcium mobilization in vitro with IC50 values below 50 nM. In vivo intrathecal injections of these antagonists during peak pain after CCI surgery reversed allodynia in male and female mice. Acute intrathecal injection of the GPR183 ligand 7α,25-OHC in naïve mice induced dose-dependent allodynia. Importantly, this effect was blocked using our novel GPR183 antagonists, suggesting spinal GPR183 activation as pronociceptive. These studies are the first to reveal a role for GPR183 in neuropathic pain and identify this receptor as a potential target for therapeutic intervention. SIGNIFICANCE STATEMENT: We have identified several novel GPR183 antagonists with nanomolar potency. Using these antagonists, we have demonstrated that GPR183 signaling in the spinal cord is pronociceptive. These studies are the first to reveal a role for GPR183 in neuropathic pain and identify it as a potential target for therapeutic intervention.
Collapse
Affiliation(s)
- Kathryn Braden
- INRAe, UMR 1280, Physiopathologie des Adaptations Nutritionnelles, CHU Hôtel-Dieu, Nantes, France (F.K.-C., M.T., K.O.) and Physiogenex SAS, Prologue Biotech, Rue Pierre et Marie Curie, Laboratoryège-Innopole, France (F.B., T.S.)
| | - Luigino Antonio Giancotti
- INRAe, UMR 1280, Physiopathologie des Adaptations Nutritionnelles, CHU Hôtel-Dieu, Nantes, France (F.K.-C., M.T., K.O.) and Physiogenex SAS, Prologue Biotech, Rue Pierre et Marie Curie, Laboratoryège-Innopole, France (F.B., T.S.)
| | - Zhoumou Chen
- INRAe, UMR 1280, Physiopathologie des Adaptations Nutritionnelles, CHU Hôtel-Dieu, Nantes, France (F.K.-C., M.T., K.O.) and Physiogenex SAS, Prologue Biotech, Rue Pierre et Marie Curie, Laboratoryège-Innopole, France (F.B., T.S.)
| | - Chelsea DeLeon
- INRAe, UMR 1280, Physiopathologie des Adaptations Nutritionnelles, CHU Hôtel-Dieu, Nantes, France (F.K.-C., M.T., K.O.) and Physiogenex SAS, Prologue Biotech, Rue Pierre et Marie Curie, Laboratoryège-Innopole, France (F.B., T.S.)
| | - Nick Latzo
- INRAe, UMR 1280, Physiopathologie des Adaptations Nutritionnelles, CHU Hôtel-Dieu, Nantes, France (F.K.-C., M.T., K.O.) and Physiogenex SAS, Prologue Biotech, Rue Pierre et Marie Curie, Laboratoryège-Innopole, France (F.B., T.S.)
| | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Latzo NG, Braden K, Giancotti L, Chen Z, DeLeon C, Boehm T, D’Cunha N, Luongo L, Doyle T, Kolar G, Walker J, Arnatt C, Salvemini D. Development of GPR183 Antagonists to Treat Neuropathic Pain. FASEB J 2020. [DOI: 10.1096/fasebj.2020.34.s1.09724] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
11
|
Stockstill K, Wahlman C, Braden K, Chen Z, Yosten GL, Tosh D, Jacobson K, Doyle T, Samson W, Salvemini D. Sexually dimorphic therapeutic response in bortezomib-induced neuropathic pain reveals altered pain physiology in female rodents. Pain 2020; 161:177-184. [PMID: 31490328 PMCID: PMC6923586 DOI: 10.1097/j.pain.0000000000001697] [Citation(s) in RCA: 20] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Chemotherapy-induced neuropathic pain (CINP) in both sexes compromises many current chemotherapeutics and lacks an FDA-approved therapy. We recently identified the sphingosine-1-phosphate receptor subtype 1 (S1PR1) and A3 adenosine receptor subtype (A3AR) as novel targets for therapeutic intervention. Our work in male rodents using paclitaxel, oxaliplatin, and bortezomib showed robust inhibition of CINP with either S1PR1 antagonists or A3AR agonists. The S1PR1 functional antagonist FTY720 (Gilenya) is FDA-approved for treating multiple sclerosis, and selective A3AR agonists are in advanced clinical trials for cancer and inflammatory disorders, underscoring the need for their expedited trials in patients with CINP as chemotherapy adjuncts. Our findings reveal that S1PR1 antagonists and A3AR agonists mitigate paclitaxel and oxaliplatin CINP in female and male rodents, but failed to block or reverse bortezomib-induced neuropathic pain (BINP) in females. Although numerous mechanisms likely underlie these differences, we focused on receptor levels. We found that BINP in male rats, but not in female rats, was associated with increased expression of A3AR in the spinal cord dorsal horn, whereas S1PR1 levels were similar in both sexes. Thus, alternative mechanisms beyond receptor expression may account for sex differences in response to S1PR1 antagonists. Morphine and duloxetine, both clinical analgesics, reversed BINP in female mice, demonstrating that the lack of response is specific to S1PR1 and A3AR agents. Our findings suggest that A3AR- and S1PR1-based therapies are not viable approaches in preventing and treating BINP in females and should inform future clinical trials of these drugs as adjuncts to chemotherapy.
Collapse
Affiliation(s)
- Katherine Stockstill
- Department of Pharmacology and Physiology, Saint Louis University School of Medicine, 1402 South Grand Blvd., St. Louis, MO 63104, USA
| | - Carrie Wahlman
- Department of Pharmacology and Physiology, Saint Louis University School of Medicine, 1402 South Grand Blvd., St. Louis, MO 63104, USA
| | - Kathryn Braden
- Department of Pharmacology and Physiology, Saint Louis University School of Medicine, 1402 South Grand Blvd., St. Louis, MO 63104, USA
| | - Zhoumou Chen
- Department of Pharmacology and Physiology, Saint Louis University School of Medicine, 1402 South Grand Blvd., St. Louis, MO 63104, USA
| | - G. L. Yosten
- Department of Pharmacology and Physiology, Saint Louis University School of Medicine, 1402 South Grand Blvd., St. Louis, MO 63104, USA
| | - D.K. Tosh
- Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892-0810, USA
| | - K.A. Jacobson
- Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892-0810, USA
| | - T.M. Doyle
- Department of Pharmacology and Physiology, Saint Louis University School of Medicine, 1402 South Grand Blvd., St. Louis, MO 63104, USA
| | - W.K. Samson
- Department of Pharmacology and Physiology, Saint Louis University School of Medicine, 1402 South Grand Blvd., St. Louis, MO 63104, USA
| | - Daniela Salvemini
- Department of Pharmacology and Physiology, Saint Louis University School of Medicine, 1402 South Grand Blvd., St. Louis, MO 63104, USA
| |
Collapse
|
12
|
Stockstill K, Doyle TM, Yan X, Chen Z, Janes K, Little JW, Braden K, Lauro F, Giancotti LA, Harada CM, Yadav R, Xiao WH, Lionberger JM, Neumann WL, Bennett GJ, Weng HR, Spiegel S, Salvemini D. Dysregulation of sphingolipid metabolism contributes to bortezomib-induced neuropathic pain. J Exp Med 2018; 215:1301-1313. [PMID: 29703731 PMCID: PMC5940258 DOI: 10.1084/jem.20170584] [Citation(s) in RCA: 86] [Impact Index Per Article: 14.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2017] [Revised: 07/31/2017] [Accepted: 03/21/2018] [Indexed: 11/04/2022] Open
Abstract
The development of chemotherapy-induced painful peripheral neuropathy is a major dose-limiting side effect of many chemotherapeutics, including bortezomib, but the mechanisms remain poorly understood. We now report that bortezomib causes the dysregulation of de novo sphingolipid metabolism in the spinal cord dorsal horn to increase the levels of sphingosine-1-phosphate (S1P) receptor 1 (S1PR1) ligands, S1P and dihydro-S1P. Accordingly, genetic and pharmacological disruption of S1PR1 with multiple S1PR1 antagonists, including FTY720, blocked and reversed neuropathic pain. Mice with astrocyte-specific alterations of S1pr1 did not develop neuropathic pain and lost their ability to respond to S1PR1 inhibition, strongly implicating astrocytes as a primary cellular substrate for S1PR1 activity. At the molecular level, S1PR1 engaged astrocyte-driven neuroinflammation and altered glutamatergic homeostasis, processes blocked by S1PR1 antagonism. Our findings establish S1PR1 as a target for therapeutic intervention and provide insight into cellular and molecular pathways. As FTY720 also shows promising anticancer potential and is FDA approved, rapid clinical translation of our findings is anticipated.
Collapse
Affiliation(s)
- Katherine Stockstill
- Department of Pharmacology and Physiology, Saint Louis University School of Medicine, St. Louis, MO
| | - Timothy M Doyle
- Department of Pharmacology and Physiology, Saint Louis University School of Medicine, St. Louis, MO
| | - Xisheng Yan
- Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, University of Georgia, Athens, GA
| | - Zhoumou Chen
- Department of Pharmacology and Physiology, Saint Louis University School of Medicine, St. Louis, MO
| | - Kali Janes
- Department of Pharmacology and Physiology, Saint Louis University School of Medicine, St. Louis, MO
| | - Joshua W Little
- Department of Pharmacology and Physiology, Saint Louis University School of Medicine, St. Louis, MO
- Department of Surgery, Center for Anatomical Science and Education, Saint Louis University School of Medicine, St. Louis, MO
| | - Kathryn Braden
- Department of Pharmacology and Physiology, Saint Louis University School of Medicine, St. Louis, MO
| | - Filomena Lauro
- Department of Pharmacology and Physiology, Saint Louis University School of Medicine, St. Louis, MO
| | | | - Caron Mitsue Harada
- Department of Pharmacology and Physiology, Saint Louis University School of Medicine, St. Louis, MO
| | - Ruchi Yadav
- Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, University of Georgia, Athens, GA
| | - Wen Hua Xiao
- Department of Anesthesiology, University of California, San Diego, La Jolla, CA
| | - Jack M Lionberger
- Department of Internal Medicine, Division of Hematology, Oncology, and Cellular Therapeutics, Saint Louis University School of Medicine, St. Louis, MO
| | - William L Neumann
- Department of Pharmaceutical Sciences, School of Pharmacy, Southern Illinois University Edwardsville, Edwardsville, IL
| | - Gary J Bennett
- Department of Anesthesiology, University of California, San Diego, La Jolla, CA
| | - Han-Rong Weng
- Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, University of Georgia, Athens, GA
| | - Sarah Spiegel
- Department of Biochemistry and Molecular Biology, Virginia Commonwealth University, School of Medicine, Richmond, VA
| | - Daniela Salvemini
- Department of Pharmacology and Physiology, Saint Louis University School of Medicine, St. Louis, MO
| |
Collapse
|
13
|
Coty B, Branham L, Cope R, Schwartz⁎ M, Wallace B, Braden K. Development, functionality, and consumer acceptance of a novel ready-to-eat lamb leg product. Meat Sci 2014. [DOI: 10.1016/j.meatsci.2013.07.042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
14
|
Wallace⁎ B, Schwartz M, Cope R, Boenig M, Branham L, Braden K. Retail shelf-life, microbial shelf-life, sensory and Warner-Bratzler-shear force analysis of selected nilgai (Boselaphus tragocamelus) muscle. Meat Sci 2014. [DOI: 10.1016/j.meatsci.2013.07.045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
15
|
Shapiro K, Ginns E, Braden K. GM1 ganglioside concentration in the cerebrospinal fluid of hydrocephalic infants and children. Z Kinderchir 1981; 34:419-24. [PMID: 7331550 DOI: 10.1055/s-2008-1063386] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
Ventricular fluid taken from 29 children with active hydrocephalus was assayed for GM1 ganglioside level and correlated with gross assessment of intellectual outcome. Normal levels of GM1 ganglioside were consistent with grossly normal intellectual function. Marked elevations of GM1 ganglioside were found in the ventricular fluid of severely retarded children. No definitive pattern of GM1 ganglioside level was found in moderately retarded children.
Collapse
|
16
|
Keusch GT, Douglas SD, Hammer G, Braden K. Antibacterial functions of macrophages in experimental protein-calorie malnutrition. II. Cellular and humoral factors for chemotaxis, phagocytosis, and intracellular bactericidal activity. J Infect Dis 1978; 138:134-42. [PMID: 98599 DOI: 10.1093/infdis/138.2.134] [Citation(s) in RCA: 30] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Cellular and humoral aspects of the antibacterial activity of macrophages during experimental protein-calorie malnutrition were studied. There were no defects in chemotaxis or bactericidal activity of cells from protein-deficient animals, although phagocytosis-associated oxygen consumption and hexose monophosphate shunt activity were depressed. However, marked impairment of humoral chemotactic factors generated in the peritoneal cavity by glycogen injection and of heatlabile serum opsonins for Staphylococcus aureus, Escherichia coli, Salmonella typhimurium, and Salmonella enteritidis was found. The studies suggested that some macrophage antibacterial functions measured in vitro are not altered in experimental acute protein-calorie malnutrition, but that serum factors, presumably complement-derived, would limit their in vivo function. Thymic involution and lymphocyte depletion would further impair in vivo cellular immune reactions affected by macrophages. This model may therefore prove useful for the study of specific aspects of cellular immunity in malnourished hosts and of specific rehabilitation strategies.
Collapse
|
17
|
Keusch GT, Douglas SD, Braden K, Geller SA. Antibacterial functions of macrophages in experimental protein-calorie malnutrition. I. Description of the model, morphologic observations, and macrophage surface IgG receptors. J Infect Dis 1978; 138:125-33. [PMID: 98598 DOI: 10.1093/infdis/138.2.125] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
An experimental protein-calorie malnutrition was produced in weanling Sprague-Dawley rats. The model resembles human malnutrition with respect to weight loss, inanition, angular stomatitis, anemia, lymphopenia, hypoproteinemia with hypoalbuminemia, and marked thymic involution. In addition, systemic invasion by gram-negative rods was documented. However, no edema was produced, and animals did not survive for longer than six weeks on the protein-deficient diet. One percent glycogen was found to be a satisfactory nonprotein stimulus for induction of a peritoneal exudate consisting primarily of young macrophages. Electron microscopy showed that morphologic events of phagocytosis and degranulation proceeded normally in macrophages from protein-deficient animals. In addition, cell surface receptors for IgG were preserved under these experimental conditions. These data indicate that weanling rats may be employed as a small animal model for servere, fulminant protein-calorie malnutrition in humans.
Collapse
|